Linagliptin: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
←Membuat halaman berisi '{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 452028402 | IUPAC_name = 8-[(3''R'')-3-Aminopiperidin-1-il]-7-(but-2-in-1-il)-3-metil-1-[(4-metilkuinazolin-2-il)metil]-3,7-dihidro-1''H''-purina-2,6-diona | image = Linagliptin.svg | width = 250 | alt = <!--Clinical data--> | pronounce = {{IPAc-en|ˌ|l|ɪ|n|ə|ˈ|g|l|ɪ|p|t|ɪ|n}} {{respell|LIN|ə|GLIP|tin}} | tradename = Tradjenta, Trajenta, Trazenta | Drugs.com = {{drugs.com|mon...' Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 34:
<!--Pharmacokinetic data-->
| bioavailability = ~30% ([[Cmax
| protein_bound = 75–99% (
| metabolism = Minimal (~10% dimetabolisme)
| metabolites =
| elimination_half-life = ~24 jam
| excretion = [[Feses]] (80%), [[urin]] (5%)<ref name="Tradjenta FDA label" />
Baris 72:
'''Linagliptin''' adalah obat yang digunakan untuk mengobati [[diabetes melitus tipe 2]] bersamaan dengan olahraga dan diet.<ref name=AHFS2019/><ref name="Neumiller_2012">{{cite journal | vauthors = Neumiller JJ | title = Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus | journal = The Annals of Pharmacotherapy | volume = 46 | issue = 3 | pages = 358–67 | date = March 2012 | pmid = 22318932 | doi = 10.1345/aph.1Q522 | s2cid = 207264493 }}</ref> Obat ini secara umum kurang disukai dibandingkan [[metformin]] dan [[sulfonilurea]] sebagai pengobatan awal.<ref name=BNF76/><ref name=AHFS2019/> Obat ini digunakan dengan cara diminum. <ref name=AHFS2019/>
[[Efek samping]] yang umum termasuk radang hidung dan tenggorokan. Efek samping yang serius mungkin termasuk [[edema angioneurotik|angioedema]], [[pankreatitis]], nyeri sendi.<ref name=BNF76/><ref name=AHFS2019/> Penggunaan pada [[kehamilan]] dan [[menyusui]] tidak dianjurkan.<ref name=BNF76>{{cite book|title=British national formulary : BNF 76|date=2018|publisher=Pharmaceutical Press|isbn=9780857113382|pages=680|edition=76}}</ref> Linagliptin adalah penghambat dipeptidil peptidase-4 yang bekerja dengan meningkatkan produksi [[insulin]] dan menurunkan produksi [[glukagon]] oleh pankreas.<ref name=AHFS2019/>
Linagliptin telah disetujui untuk penggunaan medis di Amerika Serikat,<ref>{{cite web | title=Drug Approval Package: Tradjenta (linagliptin) Tablets NDA #201280 | website=U.S. [[Food and Drug Administration]] (FDA) | date=7 June 2011 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm | access-date=3 October 2022 | archive-date=3 April 2022 | archive-url=https://web.archive.org/web/20220403111238/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/201280Orig1s000TOC.cfm | url-status=live }}</ref> Jepang, Uni Eropa, Kanada, dan Australia pada tahun 2011.<ref name=AHFS2019>{{cite web |title=Linagliptin Monograph for Professionals |url=https://www.drugs.com/monograph/linagliptin.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists |access-date=6 April 2019 |archive-date=6 April 2019 |archive-url=https://web.archive.org/web/20190406231038/https://www.drugs.com/monograph/linagliptin.html |url-status=live }}</ref><ref>{{cite web | title=10 years | website=Boehringer Ingelheim Limited | url=https://pro.boehringer-ingelheim.com/products/trajenta/10years#pre2011 | access-date=3 October 2022 | archive-date=3 October 2022 | archive-url=https://web.archive.org/web/20221003180613/https://pro.boehringer-ingelheim.com/products/trajenta/10years#pre2011 | url-status=live }}</ref>
| |||